Is Von Hippel-Lindau (VHL) disease rare?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Von Hippel-Lindau Disease Rare?

Yes, Von Hippel-Lindau (VHL) disease is classified as a rare disease, with an estimated incidence of approximately 1 in 36,000 live births and a prevalence of 1 in 46,900 individuals. 1, 2

Epidemiological Data

  • The birth incidence ranges from 1 in 27,300 to 1 in 45,500 live births across different populations, with the most commonly cited figure being 1 in 36,000. 3, 2, 4, 5

  • The prevalence in Europe is estimated at 1-9 per 100,000 individuals, making it an orphan disease by standard definitions. 4

  • VHL is significantly underdiagnosed, with many families not receiving genetic counseling or prophylactic surveillance despite meeting clinical criteria. 2

Clinical Significance Despite Rarity

While VHL is rare in absolute numbers, it represents one of the most common inherited neoplasia syndromes among hereditary cancer conditions. 6

  • Lifetime penetrance approaches 100% by age 75, meaning virtually all mutation carriers will develop manifestations if they live long enough. 1, 7

  • Approximately 80% of cases are inherited from an affected parent, while 20% arise from de novo mutations, which means absence of family history does not exclude the diagnosis. 8, 1

Impact on Morbidity and Mortality

Despite being rare, VHL has profound clinical consequences:

  • Historically, median life expectancy was only 49 years, though recent data suggests improvement to 60-67 years for those born in 2000 due to better surveillance and treatment. 8, 2

  • VHL-related tumors were the cause of death in 79% of affected individuals in historical cohorts, with renal cell carcinoma, CNS hemangioblastomas, and pancreatic neuroendocrine tumors being the primary causes of mortality. 8

  • Vision loss occurs in approximately 20% of patients from retinal hemangioblastomas if not detected and treated early. 1

References

Guideline

Von Hippel-Lindau Disease: Clinical Features and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

A Review of Von Hippel-Lindau Syndrome.

Journal of kidney cancer and VHL, 2017

Research

von Hippel-Lindau disease.

Lancet (London, England), 2003

Research

Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016

Guideline

Brain Hemangioblastomas: Incidence and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.